Published in Drug Week, June 25th, 2004
In addition, the selling stockholders have granted the underwriters a 30-day over-allotment option to purchase up to an additional 579,000 shares. All of the shares are being sold by selling stockholders. Eyetech will not sell any shares in, or receive any proceeds from, the offering.
The joint book-running managers of the offering are Merrill Lynch & Co. and Morgan Stanley, and Bear, Stearns & Co., Inc., is acting as co-manager.
Copies of the final prospectus relating to this offering...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.